47
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Seizure control by ketogenic diet-associated medium chain fatty acids

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The medium chain triglyceride (MCT) ketogenic diet is used extensively for treating refractory childhood epilepsy. This diet increases the plasma levels of medium straight chain fatty acids. A role for these and related fatty acids in seizure control has not been established. We compared the potency of an established epilepsy treatment, Valproate (VPA), with a range of MCT diet-associated fatty acids (and related branched compounds), using in vitro seizure and in vivo epilepsy models, and assessed side effect potential in vitro for one aspect of teratogenicity, for liver toxicology and in vivo for sedation, and for a neuroprotective effect. We identify specific medium chain fatty acids (both prescribed in the MCT diet, and related compounds branched on the fourth carbon) that provide significantly enhanced in vitro seizure control compared to VPA. The activity of these compounds on seizure control is independent of histone deacetylase inhibitory activity (associated with the teratogenicity of VPA), and does not correlate with liver cell toxicity. In vivo, these compounds were more potent in epilepsy control (perforant pathway stimulation induced status epilepticus), showed less sedation and enhanced neuroprotection compared to VPA. Our data therefore implicates medium chain fatty acids in the mechanism of the MCT ketogenic diet, and highlights a related new family of compounds that are more potent than VPA in seizure control with a reduced potential for side effects.

          This article is part of the Special Issue entitled ‘New Targets and Approaches to the Treatment of Epilepsy’.

          Highlights

          ► Medium chain straight and branched fatty acids were examined for seizure control in vitro. ► Structural specificity was shown for these compounds. ► Side effects were examined for active seizure-control compounds. ► In vivo seizure control, sedation and neuroprotection were shown for these compounds. ► Medium chain fatty acids relating to the MCT ketogenic diet may be active in seizure control.

          Related collections

          Most cited references63

          • Record: found
          • Abstract: found
          • Article: not found

          Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells.

          Histone deacetylases (HDACs) play important roles in transcriptional regulation and pathogenesis of cancer. Thus, HDAC inhibitors are candidate drugs for differentiation therapy of cancer. Here, we show that the well-tolerated antiepileptic drug valproic acid is a powerful HDAC inhibitor. Valproic acid relieves HDAC-dependent transcriptional repression and causes hyperacetylation of histones in cultured cells and in vivo. Valproic acid inhibits HDAC activity in vitro, most probably by binding to the catalytic center of HDACs. Most importantly, valproic acid induces differentiation of carcinoma cells, transformed hematopoietic progenitor cells and leukemic blasts from acute myeloid leukemia patients. More over, tumor growth and metastasis formation are significantly reduced in animal experiments. Therefore, valproic acid might serve as an effective drug for cancer therapy.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen.

            Valproic acid is widely used to treat epilepsy and bipolar disorder and is also a potent teratogen, but its mechanisms of action in any of these settings are unknown. We report that valproic acid activates Wntdependent gene expression, similar to lithium, the mainstay of therapy for bipolar disorder. Valproic acid, however, acts through a distinct pathway that involves direct inhibition of histone deacetylase (IC(50) for HDAC1 = 0.4 mm). At therapeutic levels, valproic acid mimics the histone deacetylase inhibitor trichostatin A, causing hyperacetylation of histones in cultured cells. Valproic acid, like trichostatin A, also activates transcription from diverse exogenous and endogenous promoters. Furthermore, valproic acid and trichostatin A have remarkably similar teratogenic effects in vertebrate embryos, while non-teratogenic analogues of valproic acid do not inhibit histone deacetylase and do not activate transcription. Based on these observations, we propose that inhibition of histone deacetylase provides a mechanism for valproic acid-induced birth defects and could also explain the efficacy of valproic acid in the treatment of bipolar disorder.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Histone deacetylase is a target of valproic acid-mediated cellular differentiation.

              Valproic acid (VPA), a well-established therapy for seizures and bipolar disorder, has recently been shown to inhibit histone deacetylases (HDACs). Similar to more widely studied HDAC inhibitors, VPA can cause growth arrest and induce differentiation of transformed cells in culture. Whether this effect of VPA is through inhibition of HDACs or modulation of another target of VPA has not been tested. We have used a series of VPA analogs to establish a pharmacological profile for HDAC inhibition. We find that VPA and its analogs inhibit multiple HDACs from class I and class II (but not HDAC6 or HDAC10) with a characteristic order of potency in vitro. These analogs also induce hyperacetylation of core histones H3 and H4 in intact cells with an order of potency that parallels in vitro inhibition. VPA and VPA analogs induce differentiation in hematopoietic cell lines in a p21-dependent manner, and the order of potency for induction of differentiation parallels the potencies for inhibition in vitro, as well as for acetylation of histones associated with the p21 promoter, supporting the argument that differentiation caused by VPA is mediated through inhibition of HDACs. These findings provide additional evidence that VPA, a well-tolerated, orally administered drug with extensive clinical experience, may serve as an effective chemotherapeutic agent through targeting of HDACs.
                Bookmark

                Author and article information

                Journal
                Neuropharmacology
                Neuropharmacology
                Neuropharmacology
                Pergamon Press
                0028-3908
                1873-7064
                1 June 2013
                June 2013
                : 69
                : 100
                : 105-114
                Affiliations
                [a ]Centre for Biomedical Sciences, School of Biological Sciences, Royal Holloway University of London, Egham, TW20 0EX, UK
                [b ]Centre for Toxicology, Faculty of Health and Medical Sciences, University of Surrey, Guildford, GU2 7XH, UK
                [c ]Department of Clinical and Experimental Epilepsy, Institute of Neurology, University College London, WC1N 3BG, UK
                Author notes
                []Corresponding author. Tel.: +44 207 1784276162; fax: +44 1784 414224. robin.williams@ 123456rhul.ac.uk
                [∗∗ ]Corresponding author. Tel.: +44 2034567890. m.walker@ 123456ucl.ac.uk
                Article
                NP4886
                10.1016/j.neuropharm.2012.11.004
                3625124
                23177536
                a886d06f-02bf-40de-bafc-fa9cbd91a634
                © 2013 Elsevier Ltd.

                This document may be redistributed and reused, subject to certain conditions.

                History
                : 9 August 2012
                : 31 October 2012
                : 2 November 2012
                Categories
                Article

                Pharmacology & Pharmaceutical medicine
                medium chain triglyceride (mct) ketogenic diet,valproic acid (vpa),seizure control,teratogenicity,neuroprotection

                Comments

                Comment on this article